Iodine-125 prostate brachytherapy (PB) is an established modality for treating localized prostate cancer (PCa), with favorable outcomes similar to those obtained by radical prostatectomy and external beam radiation therapy (EBRT).¹,² The number of PCa patients with PB has been increasing rapidly in Japan.² Gleason grading is an important predictor of PCa outcome,³ and Gleason Pattern 5 (GP5) predicts biochemical recurrence.⁴ We report the clinical outcomes of patients treated with I¹²⁵I prostate brachytherapy for clinically localized PCa and prognosis in the presence or absence of GP5.

Methods: We enrolled 316 patients with T1c–T2N0M0 PCa and undergoing prostate brachytherapy treatment. All patients were followed up for > 1 year. The primary endpoint was biochemical recurrence-free survival. Biochemical recurrence was defined by the Phoenix criteria. Survival curves were calculated by the Kaplan–Meier method, and the prognostic impact of biochemical recurrence was analyzed using a Cox proportional hazards model.

Results: The 5-year biochemical recurrence-free survival rate for all patients was 95.2%, and according to the D’Amico risk classification criteria, the rates were 98.7% for patients in low-risk, 96.9% in intermediate-risk, and 81.1% in high-risk groups (P < 0.0001). The 5-year biochemical recurrence-free survival rates for patients with GS8 or GS9–10 were 87.7% and 61.5%, respectively (P = 0.0057). Multivariate analysis found that GS and clinical T stage were independent predictors of biochemical recurrence.

Conclusions: The presence of GP5 in GS9–10 prostate cancer has a worse prognosis than GS8 prostate cancer in the absence of GP5 for patients undergoing prostate brachytherapy.

Impact of Gleason Pattern 5 on outcomes of patients with prostate cancer and iodine-125 prostate brachytherapy

Tomoyuki Makino*, Sotaro Miwa, Kiyoshi Koshida

Department of Urology, Kanazawa Medical Center, Kanazawa, Ishikawa, Japan

1. Introduction

Iodine-125 prostate brachytherapy (PB) is an established modality for treating localized prostate cancer (PCa), with favorable outcomes similar to those obtained by radical prostatectomy and external beam radiation therapy (EBRT).¹,² The number of PCa patients with PB has been increasing rapidly in Japan.² Gleason grading is an important predictor of PCa outcome,³ and Gleason scores (GS) of 8–10 represent a high-risk grade category, and Gleason Pattern 5 (GP5) predicts biochemical recurrence.⁴ but there are few reports on the impact of GP5 on clinical outcomes of patients with brachytherapy. In this report, we summarize 7 years of clinical experience and outcomes of patients with PB at our institution, and evaluate the prognostic value of GP5 with regard to biochemical recurrence.

2. Materials and methods

We enrolled 316 patients with T1c–T2N0M0 PCa and treated with PB at the Kanazawa Medical Center (Kanazawa, Japan) between 2007 and 2014. We followed the patients for ≥ 1 year. Patients were stratified into prognostic groups by D’Amico risk classification criteria.³ Low-risk patients had prostate-specific antigen (PSA) ≤ 10 ng/mL, GS ≤ 6, and clinical stage ≤ T2a tumors. Intermediate-risk patients had PSA > 10 ng/mL and ≤ 20 ng/mL, and/or GS = 7, and/or clinical stage T2b tumors. High-risk patients had PSA > 20 ng/mL and/or GS ≥ 8 and/or clinical stage ≥ T2c tumors. Most low-risk patients received PB without supplemental EBRT. High-risk patients received PB with EBRT, and intermediate-risk patients were given supplemental EBRT as determined by their physician depending on the PSA value and biopsy-positive core rate, i.e., the percentage of cores containing tumor: A total of 123 patients (30.1%) received neoadjuvant androgen deprivation therapy (ADT) for prostate volume reduction, to be worried the progression of disease until PB, or if it had already been started by...
3. Results

Patient characteristics are shown in Table 1. The median patient age was 69 years (range, 51–84 years) and the median follow-up duration was 48.2 months (range, 12–103 months). Of the 316 patients included in this study, 237 (75.0%) were in clinical stage T1c, 58 (18.4%) in T2a, 18 (5.7%) in T2b, and three (0.9%) in T2c. The median PSA level at diagnosis was 5.6 ng/mL (range, 0.67–84.44 ng/mL) and the GS were ≤ 6 (128, 40.5%), 7 (141, 44.6%), and ≥ 8 (47, 14.9%). According to the D’Amico risk criteria, 114 patients (36.1%) were at low risk, 144 (45.5%) at intermediate risk, and 58 (18.4%) at high risk. Of all patients, 221 (69.9%) were treated with PB without EBRT. A total of 123 patients (38.9%) were given neoadjuvant ADT for a median duration of 5 months. Only 10 patients (3.2%) received neoadjuvant ADT (data not shown). Additional patient characteristics, including GS, age, PSA, clinical T stage, combined EBRT therapy, and use of ADT are summarized in Table 2. Among high-risk patients, 34 (10.8%) had GS8 and all of them had no GS9.

Thirteen patients (4.1%) had GS9–10. As expected, patients with higher GS tended to have higher PSA values and a more advanced T stage.

Table 1

| Characteristic                          | Median (range)  |
|----------------------------------------|-----------------|
| Median age, y (range)                  | 51–84           |
| Clinical stage, n (%)                  | 69 (51–84)      |
| Follow-up, mo (range)                  | 12–103          |
| T1c                                    | 237 (75.0)      |
| T2a                                    | 58 (18.4)       |
| T2b                                    | 18 (5.7)        |
| T2c                                    | 3 (0.9)         |
| Gleason score, n (%)                   | 610             |
| ≤ 6                                    | 128 (40.5)      |
| ≥ 8                                    | 47 (14.9)       |
| PSA at diagnosis, ng/mL (range)        | 0.67–84.44      |
| ≤ 10                                   | 258 (81.7)      |
| 10–20                                  | 39 (12.3)       |
| ≥ 20                                   | 19 (6.0)        |
| Positive core rate, % (range)          | 7.1–100         |
| Prostate volume, mL (range)            | 7.0–46.5        |
| Neoadjuvant hormone therapy, n (%)     | 123 (38.9)      |
| Combined external beam radiotherapy, n (%) |
| Low                                   | 114 (36.1)      |
| Intermediate                           | 144 (45.5)      |
| High                                  | 58 (18.4)       |

Table 2

| Characteristic                          | n = 316 |
|----------------------------------------|---------|
| Follow-up, mo (range)                  | 12–103  |
| Clinical stage, n (%)                  | 69 (51–84) |
| T1c                                    | 237 (75.0) |
| T2a                                    | 58 (18.4) |
| T2b                                    | 18 (5.7) |
| T2c                                    | 3 (0.9) |
| Gleason score, n (%)                   | 610 |
| ≤ 6                                    | 128 (40.5) |
| ≥ 8                                    | 47 (14.9) |
| PSA at diagnosis, ng/mL (range)        | 0.67–84.44 |
| ≤ 10                                   | 258 (81.7) |
| 10–20                                  | 39 (12.3) |
| ≥ 20                                   | 19 (6.0) |
| Positive core rate, % (range)          | 7.1–100 |
| Prostate volume, mL (range)            | 7.0–46.5 |
| Neoadjuvant hormone therapy, n (%)     | 123 (38.9) |
| Combined external beam radiotherapy, n (%) |
| Low                                   | 114 (36.1) |
| Intermediate                           | 144 (45.5) |
| High                                  | 58 (18.4) |

Another physician. PB alone was administered at a dose of 145 Gy; PB with EBRT was administered at a dose of 110 Gy with an additional 45 Gy of supplemental EBRT. Planned follow-up was by PSA blood tests every 3 months for the first 2 years, and every 6 months thereafter. The primary outcome was biochemical recurrence-free survival (bRFS). Biochemical recurrence was determined by the Phoenix criteria. If biochemical recurrence was confirmed and it persisted, as shown by PSA increase, the patient was further evaluated by prostate biopsy, computed tomography, and bone scan so that recurrence could be assured and characterized by a physician. PSA bounce was defined as an increase of ≥ 0.4 ng/mL above an initial PSA nadir and a subsequent decline to or below that initial nadir without treatment, and patients meeting the bounce phenomenon were excluded from the analysis of recurrence. Survival curves were calculated by the Kaplan–Meier method, and differences in time-adjusted rates were evaluated for significance by log-rank test. The prognostic impact of biochemical recurrence was analyzed in a Cox proportional hazards model. All tests were two sided, and the statistical significance was set at \( P < 0.05 \).

4. Discussion

Since 2003, when PB was first authorized, many cancer institutes throughout Japan have registered to administer PB therapy. The reported 5-year bRFS rates for patients in the low-, intermediate-, and high-risk groups are ≥ 90%, 80–90%, and 70–80%, respectively. The corresponding bRFS rates at our treatment center were 98.7%, 96.9%, and 81.1%, respectively, which are similar to those of the previous reports.

Our high-risk patients had a poor prognosis, and those with GS9–10 PCa had a significantly worse bRFS rate than those with GS8 disease, who also had a relatively poor prognosis. In other words, the presence of GP5 predicted the worse clinical outcome. Sabolch et al. reported that the presence of GP5 predicted lower cause-specific survival and overall survival in PCa patients treated with EBRT compared with GS8 patients in cases without GP5. In that series, the presence of GP5 predicted worse clinical outcome and a short interval from biochemical failure to metastasis. In our series, six of 13 patients with GP5 experienced biochemical recurrence and four experienced advanced metastases. This suggests that GP5 may have characteristics that predispose to metastasis. Although the biological cause underlying worse outcomes in patients with GP5 is unknown, there are multiple alternative pathways that can drive a PCa toward the aggressiveness seen in the presence of GP5. Horwitz et al. reported long-term results of Radiation Therapy Oncology Group Protocol 92-02 that demonstrate a survival advantage for 24 months of ADT plus radiation therapy in the treatment of locally advanced tumors with GS of 8–10. That result implies that the Protocol 92-02 regimen should be the standard of treatment for these high-risk patients. By contrast, androgen suppression probably contributes to the elimination of occult systemic disease while also potentiating external irradiation by an additive, or supra-additive, effect on local control through induction of apoptosis. Hence, long-term ADT plus radiation therapy is considered more effective in high-risk cases.
Table 2
Clinical features stratified by Gleason score.

| Gleason score | ≤ 6 | 7 | 8 | 9, 10 |
|---------------|-----|---|---|------|
| n             | 128 (40%) | 141 (45%) | 34 (11%) | 13 (4%) |
| Median age (range) | 68 (51–84) | 69 (54–84) | 75 (54–83) | 71 (56–77) |
| Median PSA (range) | 4.98 (0.67–37.62) | 5.69 (2.00–33.96) | 7.90 (1.86–84.44) | 10.08 (4.13–62.23) |

Clinical stage
- T1c-T2a: 100% 92% 88% 62%
- T2b: 0% 6% 12% 38%
- T2c: 0% 2% 0% 0%

D’Amico risk classification
- Low: 89% 0% 0% 0%
- Intermediate: 8% 95% 0% 0%
- High: 3% 5% 100% 100%

Combined EBRT: 5% 33% 85% 100%
ADT use: 33% 43% 44% 46%

Table 3
Characteristics of recurrence patients (n = 16).

| Risk group (No. of recurrence Pts) | Median age | T stage | Gleason score | PSA | Recurrence site |
|-----------------------------------|------------|---------|---------------|-----|-----------------|
| Low                               | 72         | T1c: 5  | ≤ 6:2         | ≤ 10:7 | Local: 2 |
| 1/114; 0.9% intermediate          |            | T2a: 6  | 7:5           | > 10, ≤ 20:5 | LN: 3 |
| 5/144; 3.5%                       |            | T2b: 4  | 8:3           | > 20:4  | bone: 3 |
| High                              |            | T2c: 1  | 9–10:6        |        | Local + bone: 1 |
| 10/58; 17.2%                      |            |         |               |       | Unknown: 6 |

LN, lymph node; PSA, prostate specific antigen; Pts, patients.

Fig. 1. Survival curves calculated by the Kaplan–Meier method. (A) Survival rates for all patients (n = 316). (B) Biochemical recurrence-free survival rates for all patients stratified by the risk group. (C) Biochemical recurrence-free survival rates for all patients stratified by the Gleason score. (D) Biochemical recurrence-free survival rate for high-risk patients with a Gleason score of 8 or 9–10. GS, Gleason scores; OS, overall survival; RFS, recurrence-free survival.
such as those with GP5, in which distant micrometastasis may be present when primary therapy starts.

Gleason scoring is a well-established system for describing pathological stage and predicting oncological outcomes of men with PCa. Pierorazio et al.14 have recommended Gleason grades, and prognostic grade groups, including GS ≤ 6 (prognostic Grade Group 1); GS 3 + 4 = 7 (prognostic Grade Group 2); GS 4 + 3 = 7 (prognostic Grade Group 3); GS 4 + 4 = 8 (prognostic Grade Group 4); and GS9–10 (prognostic Grade Group 5). In that series, the 5-year bRFS rates were 96.6% in Grade Group 1, 88.1% in Group 2, 69.7% in Group 3, 63.7% in Group 4, and 34.5% in Group 5 (P < 0.001) after radical prostatectomy. Therefore, they suggested that men with GS9–10 tumors will more accurately be considered to have more aggressive tumors than those with GS8.15 In our study, the 5-year bRFS rates were 98.9% in Grade Group 1, 96.2% in Group 2, 95.3% in Group 3, 87.7% in Group 4, and 61.5% in Group 5 (P < 0.0001; Fig. 2). As above, GS were independent predictors of biochemical recurrence. The 5-year bRFS rates for patients with GS8 (i.e., Grade Group 4) or GS9–10 (i.e., Grade Group 5) were significantly different. Thus, we can mention that Grade Group 5, based on the presence of GS9, is an independent predictor of biochemical recurrence. As the biochemical prognosis is significantly worse in GS9–10 than in GS8 groups, combined modality therapy such as PB, EBRT, and long-term ADT should be considered for high-risk PCa patients with GS9 disease. A Phase III, multicenter, randomized controlled trial of trimodal therapy with 125I brachytherapy, EBRT, and short- or long-term hormone therapy for high-risk PCa is ongoing.16 We expect that the results of the short- or long-term hormone therapy for high-risk PCa study will support trimodal therapy for patients in Grade Group 5 and GS9.

This study had some limitations. First, this was a retrospective study with duration of about 7 years. Second, the follow-up period was relatively short; therefore, only biochemical recurrence was examined. Only one patient died from PCa during the observation period in this study. Future studies are thus required to examine cancer-specific survival rather than biochemical recurrence.

5. Conclusions

Although we achieved good outcomes with PB in low- and intermediate-risk patients with PCa, prognosis in the high-risk group was significantly worse. The prognosis of patients with GS9–10 based on the presence of GP5 (i.e., Grade Group 5) was worse than that for GS8 tumors (i.e., Grade Group 4), and Gleason grades may be useful for reflecting prognosis. Therefore, we should reconsider the strategy for treating patients with GS9 tumors.

Conflicts of interest

No potential conflicts of interest relevant to this article have been reported.

References

1. Potters L, Klein EA, Kattan MW, Reddy CA, Ciciki JP, Reuther AM, et al. Monotherapy for stage T1–T2 prostate cancer: radical prostatectomy, external beam radiotherapy, or permanent implantation. Radiother Oncol 2004;71:29–33.
2. Porter CR, Kodama K, Gibbons RP, Correa Jr R, Chmuk FK, Perrotte P, et al. 25-year prostate cancer control and survival outcomes: a 40-year radical prostatectomy single institution series. J Urol 2006;176:569–74.
3. Nakamura K, Ohga S, Yorozu A, Dokiya T, Saito S, Yamanaka H. Diffusion pattern of low dose rate brachytherapy for prostate cancer in Japan. Cancer Sci 2013;104:934–4.
4. Gordetsky J, Epstein J. Grading of prostatic adenocarcinoma: current state and prognostic implications. Diagn Pathol 2016;11:25.
5. Coniglio D, Hatanaka H, Yano M, Nishiyama H, Nakamura T, Kataoka N, et al. Prostate cancer after dose-escalated radiation therapy and hormonal ablation. Int J Radiat Oncol Biol Phys 2011;81:e351–60.
6. Nanda A, Chen M, Renshaw A, D’Amico AV. Gleason pattern 5 prostate cancer: Further stratification of patients with high-risk disease and implications for future randomized trials. Int J Radiat Oncol Biol Phys 2009;74:1419–23.
7. D’Amico AV, Whittington R, Malkowicz SB, Schulz D, Blank K, Broderick GA, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998;280:969–74.
8. Roach 3rd M, Hanks G, Thomas Jr H, Schellhammer P, Shipley WU, Sokol GH, et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTDOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys 2006;65:965–74.
9. Crook J, Borg J, Evans A, Toi A, Saibishkumar EP, Fung S, et al. 10-year experience with 1-125 prostate brachytherapy at the Princess Margaret Hospital: results for 1100 patients. Int J Radiat Oncol Biol Phys 2011;80:1323–9.
10. Sylvester JE, Grimm PD, Wong J, Galbreath RW, Merrick G, Blasko JC. Fifteen-year biochemical relapse-free survival, cause-specific survival, and overall survival following I-125 prostate brachytherapy in clinically localized prostate cancer: Seattle experience. Int J Radiat Oncol Biol Phys 2011;81:376–81.
11. Taira AV, Merrick GS, Butler WM, Galbreath RW, Liej J, Adamsovich E, et al. Long-term outcome for clinically localized prostate cancer treated with permanent interstitial brachytherapy. Int J Radiat Oncol Biol Phys 2011;79:1336–42.
12. Hofwall EM, Bae K, Hanks GE, Porter A, Grignon DJ, Bremeron HD, et al. Ten-year follow-up of radiation therapy oncology group protocol 92-02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer. J Clin Oncol 2008;26:2487–504.
13. Joon DL, Hasegawa M, Sikes C, Khoo VS, Terry NH, Zagosk G, et al. Supra- additive apoptotic response of R3327-C rat prostate tumors to androgen ablation and radiation. Int J Radiat Oncol Biol Phys 1997;38:1061–7.
14. Zietman AL, Prince EA, Nakfoor BM, Park JJ. Androgen deprivation and radiation therapy: sequencing studies using the Shionogi tumor system. Int J Radiat Oncol Biol Phys 1997;38:1061–7.
15. Pierorazio PM, Walsh PC, Partin AW, Epstein J. Prognostic Gleason grade grouping: data based on the modified Gleason scoring system. BJU Int 2013;111:753–60.
16. Makino et al. / GPS and 125I prostate brachytherapy

| Table 4 Multivariate Cox regression analysis for biochemical recurrence. |
|---|
| **P value** | **Hazard rate** | **95.0% CI** |
| Age ≥ 70 | 0.196 | 2.321 | 0.647 | 8.328 |
| GS ≥ 8 | 0.038 | 3.429 | 1.074 | 10.951 |
| PSA < 20 | 0.283 | 2.312 | 0.500 | 10.686 |
| T stage T3 | 0.022 | 4.587 | 1.247 | 16.868 |
| PCR > 50% | 0.932 | 0.940 | 0.227 | 3.888 |

CI, confidence interval; GS, Gleason scores; PCR, positive core rate; PSA, prostate-specific antigen.

Fig. 2. Biochemical recurrence-free survival rates for all patients stratified by Gleason grades.